Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Invasive Ductal Breast Carcinoma: early-phase trial registry
2 of 5 indexed Invasive Ductal Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Invasive Ductal Breast Carcinoma: 5 US clinical trials tracked, 2 recruiting.
Invasive Ductal Breast Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition invasive-ductal-breast-carcinoma
OPEN 2 | RECR 40% | LATE 1 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Invasive Ductal Breast Carcinoma lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Invasive Ductal Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Invasive Ductal Breast Carcinoma is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Invasive Ductal Breast Carcinoma research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Invasive Ductal Breast Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Invasive Ductal Breast Carcinoma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT04084730
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Memorial Sloan Kettering Cancer Center
NCT05837767
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
NCT01953588
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
NCT01791478
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
University of Chicago
NCT01706432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Invasive Ductal Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Invasive Ductal Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Invasive Ductal Breast Carcinoma page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Invasive Ductal Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Invasive Ductal Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Invasive Ductal Breast Carcinoma condition card totals 5 registered trials; most-linked intervention laboratory biomarker analysis; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.